↓ Skip to main content

Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -

Overview of attention for article published in Radiation Oncology, December 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -
Published in
Radiation Oncology, December 2014
DOI 10.1186/s13014-014-0302-7
Pubmed ID
Authors

Nobumichi Tanaka, Kazumasa Torimoto, Isao Asakawa, Makito Miyake, Satoshi Anai, Akihide Hirayama, Masatoshi Hasegawa, Noboru Konishi, Kiyohide Fujimoto

Abstract

BackgroundTo evaluate the effect of two different alpha-1 adrenoceptor antagonists on lower urinary tract symptoms in patients who underwent LDR-brachytherapy.MethodsA total of 141 patients who had been clinically diagnosed with localized prostate cancer and underwent LDR-brachytherapy between were enrolled. Patients were randomized and allocated to two groups (silodosin 8 mg vs. naftopidil 75 mg). The primary endpoint was a change in the international prostate symptom score (IPSS) at 3 months after seed implantation. Secondary endpoints included the recovery rate of IPSS at 12 months after seed implantation, the change in IPSS and overactive bladder symptom score, uroflowmetric parameters, and frequency volume chart (FVC). To determine independent variables that can predict IPSS recovery, logistic regression analysis was carried out.ResultsThe mean change in the IPSS at 3 months after seed implantation in both groups was ¿10.6 (naftopidil) and ¿10.4 (silodosin), respectively. There was not a significant difference between the two groups (p=0.728). An increase in urinary frequency and a decrease in total urinated volume and mean voided volume were observed in FVC for 12 months after seed implantation. Multivariate analysis revealed that the urethral dose (UD30) was an independent predictive parameter of IPSS recovery. Patients with UD30¿<¿200Gy showed a higher recovery rate of IPSS at 12 months after seed implantation.ConclusionThere was no significant difference of serial change in IPSS between silodosin and naftopidil during the first year after seed implantation. A lower dose on the urethra was an independent predictor of IPSS recovery at 12 months after seed implantation.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 23%
Unspecified 2 15%
Researcher 2 15%
Student > Master 2 15%
Student > Ph. D. Student 1 8%
Other 3 23%
Readers by discipline Count As %
Medicine and Dentistry 7 54%
Unspecified 3 23%
Nursing and Health Professions 1 8%
Agricultural and Biological Sciences 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2014.
All research outputs
#5,721,233
of 7,918,051 outputs
Outputs from Radiation Oncology
#755
of 1,066 outputs
Outputs of similar age
#144,349
of 237,689 outputs
Outputs of similar age from Radiation Oncology
#60
of 83 outputs
Altmetric has tracked 7,918,051 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,066 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,689 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.